IDOR 11342831
Alternative Names: IDO-090; IDOR-1134-2831Latest Information Update: 31 Oct 2023
At a glance
- Originator Idorsia Pharmaceuticals
- Class Bacterial vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Clostridium difficile infections
Most Recent Events
- 19 Sep 2023 Preclinical trials in Clostridium difficile infections in Switzerland (Parenteral), prior to September 2023 (Idorsia Pharmaceuticals pipeline, September 2023)
- 19 Sep 2023 Idorsia Pharmaceuticals plans a phase I trial for Clostridium difficile infections(Prevention) (Parenteral) (Idorsia Pharmaceuticals pipeline, September 2023)